Featured Publications

Leveraging a deep bench of expertise and foundational experience in DNA medicine development, we’re driving research that has the potential to transform treatment paradigms and improve patients’ lives.

DNA Immunotherapy (INO-3107) Results in Long-Term Surgery Reduction in RRP

The Laryngoscope
August 2025

DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107

Nature Communications
February 2025

Vaccines for HPV-associated diseases

Molecular Aspects of Medicine
December 2023

Interim Results of a Phase 1/2 Open-Label Study of INO-3107 for HPV-6 and/or HPV-11-Associated Recurrent Respiratory Papillomatosis

The Laryngoscope
May 2023

Other Development Candidates

Title	Disease Target	Product
DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity JCI Insight — April 2019	HER2
Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape Molecular Therapy - Oncolytics — March 2023	Glioblastoma Multiforme	EGFRvIII-DBTE
Engineered antibody cytokine chimera synergizes with DNA-launched nanoparticle vaccines to potentiate melanoma suppression in vivo Frontiers in Immunology — February 2023	Melanoma	Antibody-cytokine chimera TA99-HL2-KOA1 with DLnano-vaccine

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases